Adults with obesity lost 10.2% of their body weight at 4 years with the GLP-1 receptor agonist semaglutide, according to an analysis of data from the SELECT trial.
As Healio previously reported, the SELECT trial randomly assigned 17,604 adults with obesity and established cardiovascular disease to once-weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk) or placebo. In the trial’s primary
Are drugs or surgery superior for obesity treatment? healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
News you may have missed from the 2023 Cardiometabolic Health Congress healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
CMHC spotlights impact of digital health, social determinants on cardiometabolic care healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Obesity Forum®: Getting Engaged in Obesity Care healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.